Inhibition of <i>Pseudomonas aeruginosa</i> Alginate Synthesis by Ebselen Oxide and Its Analogues

Abstract

<i>Pseudomonas aeruginosa</i> is a Gram-negative opportunistic pathogen that is frequently found in the airways of cystic fibrosis (CF) patients due to the dehydrated mucus that collapses the underlying cilia and prevents mucociliary clearance. During this life-long chronic infection, <i>P. aeruginosa</i> cell accumulates mutations that lead to inactivation of the <i>mucA</i> gene that results in the constitutive expression of <i>algD-algA</i> operon and the production of alginate exopolysaccharide. The viscous alginate polysaccharide further occludes the airways of CF patients and serves as a protective matrix to shield <i>P. aeruginosa</i> from host immune cells and antibiotic therapy. Development of inhibitors of alginate production by <i>P. aeruginosa</i> would reduce the negative impact from this viscous polysaccharide. In addition to transcriptional regulation, alginate biosynthesis requires allosteric activation by bis (3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP) binding to an Alg44 protein. Previously, we found that ebselen (Eb) and ebselen oxide (EbO) inhibited diguanylate cyclase from synthesizing c-di-GMP. In this study, we show that EbO, Eb, ebsulfur (EbS), and their analogues inhibit alginate production. Eb and EbS can covalently modify the cysteine 98 (C98) residue of Alg44 and prevent its ability to bind c-di-GMP. However, <i>P. aeruginosa</i> with Alg44 C98 substituted with alanine or serine was still inhibited for alginate production by Eb and EbS. Our results indicate that EbO, Eb, and EbS are lead compounds for reducing alginate production by <i>P. aeruginosa</i>. Future development of these inhibitors could provide a potential treatment for CF patients infected with mucoid <i>P. aeruginosa</i>.